Last reviewed · How we verify
CD19 t-haNK- IV Administration
CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system.
CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system. Used for Relapsed or refractory B-cell malignancies.
At a glance
| Generic name | CD19 t-haNK- IV Administration |
|---|---|
| Sponsor | ImmunityBio, Inc. |
| Drug class | CAR T-cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD19 t-haNK- is a chimeric antigen receptor (CAR) T-cell therapy that specifically targets cancer cells expressing the CD19 protein. This approach involves genetically modifying a patient's T-cells to recognize and bind to CD19, leading to the activation of the immune system and the subsequent destruction of cancer cells.
Approved indications
- Relapsed or refractory B-cell malignancies
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
Key clinical trials
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
- Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19 t-haNK- IV Administration CI brief — competitive landscape report
- CD19 t-haNK- IV Administration updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI